Pacira | PCRX - Sales Revenues


Pacira reported $196.87M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Assertio Holdings USD 29.2M 1.92M Sep/2024
Astellas Pharma JPY 571.21B 46.89B Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Coherus Biosciences USD 7.6M 46.54M Mar/2025
Heron Therapeutics USD 32.81M 3.21M Sep/2024
Ironwood Pharmaceuticals USD 47.71M 74.35M Dec/2025
J&J USD 24.6B 610M Dec/2025
Ligand Pharmaceuticals USD 59.66M 55.8M Dec/2025
Nektar Therapeutics USD 24.12M 635K Sep/2024
Novo Nordisk DKK 79.14B 4.16B Dec/2025
Pacira USD 196.87M 17.35M Dec/2025
Perrigo USD 1.11B 70M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Supernus Pharmaceuticals USD 211.6M 19.5M Dec/2025
Teva Pharmaceutical Industries USD 14.63B 10M Dec/2025
Xeris Pharmaceuticals USD 74.38M 2.84M Sep/2025
Xoma USD 25K 5M Sep/2024
Zoetis USD 2.4B 0 Dec/2025